Dublin, June 21, 2024 (GLOBE NEWSWIRE) — The “Adeno Virus Gene Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034” report has been added to ResearchAndMarkets.com’s The offer of
The top 7 adeno-associated virus gene therapy markets reached a value of US$ 1.9 billion in 2023 and is projected to reach US$ 75.1 billion by 2034, exhibiting a CAGR of 50.46% during 2023-2034.
The growing ability of AAV gene therapy to treat a wide range of disorders, including inherited diseases, certain types of cancer, and multiple viral infections, is majorly driving the global adenovirus gene therapy market. In addition, the growing popularity of the AAV vector due to its several unique features that are useful in clinical applications, including low immunogenicity, broad tropism, and ease of production, is further creating a positive outlook for the market. AAV is also nonpathogenic, rarely integrates into the host chromosome, and results in long-term transgene expression.
Additionally, various key players are investing extensively in AAV gene therapy research and development activities for high-yield producer cell lines, which would enable improved quality and more flexible viral vector production at a lower cost. low. This, in turn, is further acting as an important growth driving factor. Additionally, the growing use of AAV gene therapy for personalized treatment as it can be easily tailored to the patient’s specific genetic mutation, leading to more effective treatment, is also boosting the global market. Additionally, ongoing advancements in the biotechnology and genetics sectors, such as modifying the efficiency of AAV transduction by optimizing the transgene cassette and using capsid engineering to enhance vector tropism, are expected to drive the global adenovirus gene therapy market. related in the coming years.
This report provides an analysis of the adeno-associated virus gene therapy market in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan. This includes treatment practices, marketed drugs and pipeline drugs, share of individual therapies, market performance in seven major markets, market performance of major companies and their drugs, etc.
The report also provides the current and future patient pool in seven key markets. According to the report, the United States has the largest patient pool for adeno-associated virus gene therapy and also represents the largest market for its treatment.
Furthermore, current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. are also given in the report. This report is a must read for manufacturers, investors, business strategists, researchers, consultants and all those who have any kind of stake or are planning to enter the adeno-associated virus gene therapy market in any way.
Time period of the study
- Base year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Places Covered
- United States
- Germany
- France
- United Kingdom
- Ital
- Spain
- Japan
Analysis covered in each country
- Historical, current and future epidemiological scenario
- Historical, current and future performance of adeno-associated virus gene therapy market
- Historical, current and future performance of various therapeutic categories in the market
- Sales of various drugs in the adeno-associated virus gene therapy market
Competitive Landscape:
This report also provides a detailed analysis of current marketed adenovirus-related gene therapy drugs and late-stage pipeline drugs.
Drugs on the market
- Drug overview
- Mechanism of action
- Regulatory status
- Clinical trial results
- Drug intake and market performance
Late-stage drugs in the pipeline
- Drug overview
- Mechanism of action
- Regulatory status
- Clinical trial results
- Drug intake and market performance
Main attributes:
| The report attribute | The details |
| number of pages | 129 |
| Forecast period | 2023 – 2034 |
| Estimated market value (USD) in 2023 | 1.9 billion dollars |
| Projected market value (USD) by 2034 | 75.1 billion dollars |
| Compound Annual Growth Rate | 39.7% |
| Regions covered | global |
Key questions answered in this report:
Market Insights
- How has the adeno-associated virus gene therapy market performed so far and how will it perform in the coming years?
- What were the market shares of various therapeutic segments in 2023 and how are they expected to perform by 2034?
- What was the size of the Adeno-associated virus gene therapy market across the top seven markets in 2023, and what will it be in 2034?
- What is the growth rate of the adeno-associated virus gene therapy market in the top seven markets and what will be the expected growth rate over the next ten years?
- What are the main unmet needs in the market?
Insights into Epidemiology
- What is the number of cases (2018-2034) going for adeno-associated virus gene therapy in the top seven markets?
- What is the number of cases (2018-2034) going for adeno-associated virus gene therapy by age in the top seven markets?
- What is the number of cases (2018-2034) going for adeno-associated virus gene therapy by gender in the top seven markets?
- What is the number of cases (2018-2034) going for adeno-associated virus gene therapy by type in the top seven markets?
- How many patients were diagnosed (2018-2034) with adenovirus-associated gene therapy in the top seven markets?
- What Is the Size of the Adeno-Associated Virus Gene Therapy Patient Pool (2018-2023) in the Top Seven Markets?
- What would be the projected patient population (2024-2034) in the top seven markets?
- What are the main factors driving the epidemiologic trend of adeno-associated virus gene therapy?
- What will be the rate of patient growth in the top seven markets?
Adenovirus-associated gene therapy: Current treatment scenario, marketed drugs, and emerging therapies
- What are the current marketed drugs and how are they performing in the market?
- What are the top drugs in the pipeline and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for adeno-associated virus gene therapy drugs in the seven major markets?
- What are the leading companies in the market and what are their market shares?
- What are the major mergers and acquisitions, licensing activities, collaborations, etc. related to adeno-associated virus gene therapy market?
- What are the key regulatory events related to Adeno-Associated Virus Gene Therapy market?
- What is the clinical trial landscape structure by status related to Adeno-associated virus gene therapy market?
- What is the clinical trial landscape structure by phase related to Adeno-associated virus gene therapy market?
- What is the clinical trial landscape structure by route of administration for adeno-associated virus gene therapy market?
For more information about this report, visit https://www.researchandmarkets.com/r/gchwtb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, leading companies, new products and the latest trends.
-
Adeno-Associated Virus Gene Therapy Market
#AdenoAssociated #Virus #Gene #Therapy #Market #Report #Epidemiology #Industry #Trends #Forecasts
Image Source : www.globenewswire.com